🚀 VC round data is live in beta, check it out!
Cybin Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cybin and similar public comparables like Aclaris Therapeutics, Adlai Nortye, Antibiotice, Binex and more.
Cybin Overview
Founded
N/A
HQ
—
Employees
50
Website
N/A
Financials (LTM)
EV
$275M
Cybin Financials
Cybin reported last 12-month revenue of — and negative EBITDA of ($132M).
In the same LTM period, Cybin generated — in gross profit, ($132M) in EBITDA losses, and had net loss of ($136M).
Revenue (LTM)
Cybin P&L
In the most recent fiscal year, Cybin reported revenue of — and net income of —.
Cybin expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($132M) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($136M) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cybin Stock Performance
Cybin has current market cap of $330M, and enterprise value of $275M.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $275M | $330M | — | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCybin Valuation Multiples
Cybin trades at (2.1x) EV/EBITDA.
Cybin Financial Valuation Multiples
As of March 7, 2026, Cybin has market cap of $330M and EV of $275M.
Equity research analysts estimate Cybin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cybin has a P/E ratio of (2.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $330M | XXX | $330M | XXX | XXX | XXX |
| EV (current) | $275M | XXX | $275M | XXX | XXX | XXX |
| EV/EBITDA | (2.1x) | XXX | — | XXX | XXX | XXX |
| EV/EBIT | (2.1x) | XXX | — | XXX | XXX | XXX |
| P/E | (2.4x) | XXX | — | XXX | XXX | XXX |
| EV/FCF | (2.0x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cybin Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cybin Margins & Growth Rates
Cybin's revenue in the last fiscal year grew by —.
Cybin's revenue per employee in the last FY averaged $0.0M.
Cybin Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 28% | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cybin Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Digital Therapeutics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Aclaris Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Adlai Nortye | XXX | XXX | XXX | XXX | XXX | XXX |
| Antibiotice | XXX | XXX | XXX | XXX | XXX | XXX |
| Binex | XXX | XXX | XXX | XXX | XXX | XXX |
| Foghorn Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cybin M&A Activity
Cybin acquired XXX companies to date.
Last acquisition by Cybin was on XXXXXXXX, XXXXX. Cybin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cybin
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCybin Investment Activity
Cybin invested in XXX companies to date.
Cybin made its latest investment on XXXXXXXX, XXXXX. Cybin invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cybin
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cybin
| How many employees does Cybin have? | As of today, Cybin has over 50 employees. |
| Is Cybin publicly listed? | Yes, Cybin is a public company listed on NYSE American. |
| What is the stock symbol of Cybin? | Cybin trades under CYBN ticker. |
| When did Cybin go public? | Cybin went public in 2020. |
| Who are competitors of Cybin? | Cybin main competitors are Aclaris Therapeutics, Adlai Nortye, Antibiotice, Binex. |
| What is the current market cap of Cybin? | Cybin's current market cap is $330M. |
| Is Cybin profitable? | No, Cybin is not profitable. |
| What is the current EBITDA of Cybin? | Cybin has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Cybin? | Current EBITDA multiple of Cybin is (2.1x). |
| What is the current FCF of Cybin? | Cybin's last 12 months FCF is ($139M). |
| What is the current EV/FCF multiple of Cybin? | Current FCF multiple of Cybin is (2.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.